source
- Novartis signs up to $900 million deal with China's BoomRay for preclinical radioligand therapyNovartis has licensed a preclinical radioligand therapy from BoomRay Pharmaceuticals, a Suzhou‑based biotech, in a deal that could be worth up to $900 million. The agreement includes an undisclose…
- FDA panel questions effectiveness of Grail's early-cancer detection testFDA's Molecular and Clinical Genetics Panel and agency officials raised concerns about Grail's next-generation sequencing test designed to detect multiple cancers early in adults over 50. The advi…